Oncology
Partnership Success Story
Prominent clinical-stage biotech combines Judi for Eligibility and Judi for Adjudication on pivotal Phase 2 CAR-T oncology trial with over 600 endpoints
DownloadDownloadFeb 15, 2024
Whether you need to transmit and review solid tumor images for a pivotal Phase III Oncology trial, determine patient eligibility with a central review committee for a rare disease study, or collaborate with colleagues across the globe to reliably process clinical events for adjudication in an area with novel endpoints, Judi is the advantage more biopharmaceutical and medical device sponsors are trusting to support mission-critical process management.
From early stage to post-marketing registry trials, leading biopharma and medical device sponsors have relied on the flexibility of Judi to facilitate development of today’s leading medicines. See how Judi can help your clinical project or program below.
For over 15 years, Judi by AG Mednet has partnered with most of the world’s biopharmaceutical and medical device trial sponsors to advance and improve patient outcomes through successful clinical development.
Unlike legacy "platform" providers, Judi was designed from the ground-up to solve for the dynamic variability of clinical conduct and process required in any phase or therapeutic area. Judi is always configured to adapt to your process—not ours.
Secure, compliant data management and audit trails provide the confidence of today’s regulatory environment. Judi is HIPAA, GDPR, SOC-2, and 21 CFR Part 11 compliant.
Leveraging the power and flexibility of Judi’s solutions has become a standard at most major biopharmaceutical and CRO entities. No matter the size, phase, or complexity of the clinical project or program, working with AG Mednet means you’ll have more than a technology partner, you’ll have an ally that values the nuances of your work as much as you do.
